NCT05641064 is a Phase 3 clinical trial of Dexmedetomidine 0.5mcg/kg/h in Systemic Inflammatory Response, sponsored by University Hospital Dubrava.

Who is sponsoring NCT05641064?

NCT05641064 is sponsored by University Hospital Dubrava.

What drugs are being tested in NCT05641064?

Interventions in NCT05641064: Placebo, Dexmedetomidine 0.5mcg/kg/h, Dexmedetomidine 1 mcg/kg/h.

What condition does NCT05641064 study?

NCT05641064 studies Systemic Inflammatory Response, Aortic Valve Stenosis.

Is NCT05641064 still recruiting?

NCT05641064 is currently completed. Last updated 30 March 2025.

Last reviewed 2025-03-30 · How we verify

NCT05641064

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Intraoperative Dexmedetomidine Use in Patients Undergoing Surgical Aortic Valve Replacement

Completed Phase 3 Last updated 30 March 2025

What this trial tests

Phase 3 trial testing Placebo in Systemic Inflammatory Response in 60 participants. Completed in 22 September 2024.

Timeline

22 November 2022

Primary endpoint
22 September 2024

22 September 2024

Quick facts

Lead sponsor	University Hospital Dubrava
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	22 November 2022
Primary completion	22 September 2024
Estimated completion	22 September 2024
Sites	1 location across Croatia

Drugs / interventions tested

Placebo
Dexmedetomidine 0.5mcg/kg/h — full drug profile →
Dexmedetomidine 1 mcg/kg/h — full drug profile →

Conditions studied

Systemic Inflammatory Response — all drugs for Systemic Inflammatory Response →
Aortic Valve Stenosis — all drugs for Aortic Valve Stenosis →

Sponsor

University Hospital Dubrava

Who can join

Adults 18 to 85, any sex, with Systemic Inflammatory Response or Aortic Valve Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim of this randomized prospective study is to investigate the immunomodulatory effects of dexmedetomidine on outcomes in patients with isolated aortic stenosis after surgical aortic valve replacement.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of Dexmedetomidine on Cardiopulmonary Bypass Induced Inflammatory Response in Patients Undergoing Aortic Valve Replacement.
Safaric Oremus Z, Bradic N, Gospic I, Presecki I, et al · · 2025 · cited 1× · PMID 40283079 · DOI 10.3390/life15040524

Verify or expand the search:

Other recruiting trials for Systemic Inflammatory Response

Currently open trials in the same condition.

NCT06955975 — The Effect of Pectin Supplementation on Geriatric With Frailty: A Randomised Placebo-Controlled Dietary Intervention Stu · NA · recruiting
NCT06542393 — PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG) · Phase 2 · recruiting

Other University Hospital Dubrava trials

Trials by the same sponsor.

NCT07506304 — Biological Potentials in Arthroscopic All-inside Semitendinosus Anterior Cruciate Ligament Reconstruction · NA · not yet recruiting
NCT07389434 — Feasibility, Safety, Cost-effectiveness, and Environmental Impact of Reprocessed Ablation Catheters in PVI · NA · recruiting
NCT07339449 — Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients · NA · recruiting
NCT06969586 — The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy · enrolling by invitation
NCT06960629 — The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05641064 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Dubrava
Last refreshed: 30 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05641064.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing